These four Houstonians are among the best researchers in the state. Image via Getty Images

Four Houston scientists were named among a total of five Texas rising stars in research by the Texas Academy of Medicine, Engineering, Science & Technology, or TAMEST, last month.

The group will be honored at the 2023 Edith and Peter O’Donnell Awards by TAMEST in May. According to Edith and Peter O’Donnell Committee Chair Ann Beal Salamone, the researchers "epitomize the Texas can-do spirit."

The Houston winners include:

Medicine: Dr. Jennifer Wargo

A physician and professor of surgical oncology and genomic medicine at The University of Texas MD Anderson Cancer Center, Wargo was named a 2023 honoree for her discoveries surrounding the "important connection between treatment outcomes and a patient’s gut microbiome," according to a statement from TAMEST.

Engineering: Jamie Padgett

The Stanley C. Moore Professor of Engineering at Rice University, Padgett was honored for her work that aims to "enhance reliability and improve the sustainability of critical community infrastructure" through developing new methods for multi-hazard resilience modeling.

Physical sciences: Erez Lieberman Aiden

As a world-leading biophysical scientist and an associate professor of molecular and human genetics at Baylor College of Medicine, is being honored for his work that has "dramatically impacting the understanding of genomic 3D structures." He is working with BCM to apply his findings to clinical settings, with the hope that it will eventually be used to treat disease by targeting dark matter in the body.

Technology innovation: Chengbo Li

As a geophysicist at ConocoPhillips, Li is being recognized for innovations in industry-leading Compressive Seismic Imaging (CSI) technology. "This CSI technology allows the oil and gas industry to produce these seismic surveys in less time, with less shots and receivers, and most importantly, with less of an environmental impact," his nominator Jie Zhang, founder and chief scientist of GeoTomo LLC, said in a statement.


James J. Collins III at UT Southwestern Medical Center in Dallas was also named this year's rising star in the biological sciences category for his research on schistosomiasis, a disease that impacts some of the world’s poorest individuals.

The O'Donnell Awards have granted more than $1.5 million to more than 70 recipients since they were founded in 2006. Each award includes a $25,000 honorarium and an invitation to present at TAMEST’s Annual Conference each year, according to TAMEST's website.

The awards expanded in 2002 to include both a physical and biological sciences award each year, thanks to a $1.15 million gift from the O’Donnell Foundation in 2022.

Balancing is important throughout your life, and Zibrio has the tools and tips for you to use to stay centered. Pexels

Houston medical devices company using NASA balancing technology prepares for commercial launch

From space to marketplace

In her postdoctoral work at NASA, Katharine Forth and her colleague were tasked with finding a new way to track the balance of astronauts on the moon.

"The machines typically used for balance measurement can be as large as a telephone booth, so we invented a new way to measure postural control using a much smaller mechanism that fit inside a moon boot," Forth says.

She didn't know it at the time, but working on this technology would lead her to create Zibrio, The Balance Company with her colleague, Erez Lieberman Aiden.

Zibrio is a health company that aims to be the gold standard of measuring balance. The Zibrio scale calculates users' weight like a typical scale and rates their balance on scale of 1 to 10.

The scale gathers data from your weight, your postural control, your muscles and other factors to calculate the rating. Andrea Case-Rogers, chief experience officer at Zibrio, describes a perfect rating of 10 as elusive for most, or "Simone Biles on a good day."

After seeing their rating, users can identify any problems and start taking steps to improve their balance. Zibrio will also come with a smartphone app, so users can track their balance, any fluctuations and progress over a long-term period.

By using the scale and app together, users can gain a greater understand of what in their lifestyle is helping versus hurting their balance.

From space to the marketplace
After co-founding Zibrio together in 2015, Forth and Aiden have taken the company a long way since then.

Zibrio is a finalist for the 2019 SXSW Pitch in the health and wearables category. In 2015, the company was part of the Texas Medical Center's TMCx medical devices cohort. Both programs highlight the innovative technology being used as well as the big impact that Zibrio could have for both consumers and clinicians.

Zibrio already has conducted clinical trials all over Houston by working with Memorial Hermann and UT Physicians, and the company is currently focused on fundraising. Forth and her team of five will use these funds to get the scale and smartphone app consumer-ready and launched.

The commercial launch for both the scale and app is planned for later this year.

"We're currently finalizing the design with the manufacturer, so they can make the scale available commercially," Forth says. "Since 2015, we've been fundraising, building prototype scales and conducting clinical trials."

Finding balance at any age
A common misconception is that our balance deteriorates in older age. In actuality, a lifetime of behavior and activity affects our balance in later years. Falls are the leading cause of accidental death and unexpected injuries in older adults.

"If you have been mostly sedentary your whole life, by the time you hit your later years, your lower limb strength is weakened affecting your ability to move." Forth says, "so many factors feed into your balance, which means there are so many things that can be done to lower your fall risk."

When Forth and her team ran a balance program at a senior living facility, they halved the number of falls in two years. By creating an awareness of balance, they were able to drive changed behaviors in the seniors, in turn, improving their balance.

According to Case-Rogers, Zibrio is bringing the balance conversation to people in 60s and 70s who want to keep their lifestyle and not deal with mobility and health issues later. They want to show investors that there is a market for wellness product like Zibrio among older people.

Zibrio will sponsor the National Senior Games, the largest multi-sport competition for seniors in the world, this summer in Albuquerque. With over 10,000 athletes, Forth and her team are excited to introduce Zibrio to a larger audience.

Forth firmly believes balance measurements should be a part of routine wellness exams and home self-monitoring, especially in later years.

"When athletes stand on a scale and see their number, it's like a light goes on in their heads and they realize how important balance is," says Forth. "That's what I love, we have this great product that opens up the conversation about and is really helping people in middle age and beyond."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.

Axiom Space tops $525M in oversubscribed round, announces Swiss subsidiary

funding boost

Axiom Space tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million.

Axiom shared in February that it had secured $350 million in a financing round led by Type One Ventures and Qatar Investment Authority. In the latest release from the company, Axiom reports that Japan-based MUFG Bank Ltd. joined the round as a new investor, in addition to continued participation from existing backers.

The funding will go toward developing the company's commercial space station, known as Axiom Station, and the production of its Axiom Extravehicular Mobility Unit (AxEMU) under its NASA spacesuit contract.

“Investor interest in this round outpaced what we set out to raise, which speaks to the moment we’re in,” Jonathan Cirtain, CEO and president of Axiom Space, said in the news release. “Our partners see what is possible in low-Earth orbit, and they see who is positioned to lead it.”

Axiom announced last month that it planned to open a Japanese subsidiary July 1. Earlier this week, it also shared plans to establish Axiom Space Switzerland, a wholly owned subsidiary based in Lucerne that is also expected to begin operations this summer.

The Switzerland subsidiary aims to establish Axiom's presence in Europe and help it partner with the European Space Agency and other space organizations and companies on the continent.

“Europe is a founding leader in the creation of the commercial space economy, and Switzerland is uniquely positioned to convene the government agencies, research institutions, and industrial entities that will shape its next decade,” Cirtain added in a separate release. “Axiom Space Switzerland facilitates the scaling of development and deployment of the infrastructure that will succeed the International Space Station.”

Texas cashes in among 10 best U.S. state economies in 2026 report

State Economics

A new study gauging the success or decline in economic performance in every state has revealed Texas' economy remains stable in 2026 after it dropped out of the top five to No. 8 last year.

Texas boasts the No. 8 best state economy in the U.S. this year, according to WalletHub's annual "Best & Worst State Economies" report. The personal finance website's analysts ranked all 50 states and the District of Columbia across 28 relevant metrics to measure each state's economic activity and health status, and its "innovation potential."

Notably, Texas leads the nation for the most exports per capita in the U.S. in a five-way tie with Louisiana, Kentucky, North Dakota, and Indiana. Across the study's three main categories, Texas ranked highly for its economic activity (No. 7) and economic health (No. 11), and the state's "innovation potential" rank is the 24th best in the nation.

This is how WalletHub ranked Texas' economic performance, where No. 1 is considered the best and No. 25 is considered average:
  • No. 6 – Change in non-farm payrolls
  • No. 8 – Change in GDP
  • No. 8 – Startup activity
  • No. 11 – Annual median household income
  • No. 18 – Government surplus/deficit per capita
  • No. 21 – Percentage of jobs in high-tech industries
  • No. 30 – Unemployment rate
WalletHub previously ranked Texas one of the top three states to start a business in 2026, with Houston earning its own entrepreneurial acclaim in separate rankings of the best big cities for new businesses and for starting a career.

"U.S. economic growth depends heavily on the performance of individual states, and some contribute more than others," the report's author wrote. "For example, California, Texas, New York and Florida have economies so large that if they were countries, they would rank in the top 20 in the world."

The five states with the worst state economies in 2026 are Rhode Island (No. 47), Maine (No. 48), Louisana (No. 49), Kentucky (No. 50), and West Virginia (No. 51).

The top 10 best state economies for 2026 are:

  • No. 1 – Massachusetts
  • No. 2 – Washington
  • No. 3 – Utah
  • No. 4 – California
  • No. 5 – Delaware
  • No. 6 – North Carolina
  • No. 7 – New York
  • No. 8 – Texas
  • No. 9 – Colorado
  • No. 10 – Florida

---

This article originally appeared on CultureMap.com.